Lonza Signs 15-year Lease of the 42,000 sq ft Gonville Building at Chesterford Research Park
 

Cambridge, UK, 06 August 2019: Chesterford Research Park is delighted to welcome Lonza to Chesterford Research Park.

The Swiss multinational CDMO, which provides contract development and manufacturing services to the pharmaceutical and biotech industries, has signed a 15-year lease of the 42,000 sq ft Gonville building, an impressive two-winged building, linked by a central reception block. Situated at the heart of the Park and within easy reach of The Nucleus central facilities building, the Gonville Building is ideally positioned to ensure Lonza staff are able to take full advantage of all that Chesterford Research Park has to offer.

The move to Chesterford will enable Lonza to expand its capabilities to support risk assessment and development of early stage biotherapeutics and vaccines. With the market witnessing a growing pipeline of increasingly complex biologic medicines, Lonza is driving new solutions to enable its customers to move quickly and effectively towards treating patients in clinical trials.

Rob Sadler, Head of Savills Cambridge Office commented: “This is a significant move for Lonza as a major customer within the cluster. The fact that we have been able to pre-let the Gonville Building is testament not only to the strength of the market, but also to the Park itself. We are seeing significant interest in Chesterford from a number of sources, as evidenced by this and other recent deals. The Newnham Building for example, which is currently being completely refurbished has garnered significant interest – so much so that one suite is now confirmed as pre-let to Isomerase, and of the remaining three two are currently under offer, despite the fact that the building is not due for completion until 2020. Given the intensity of interest in Chesterford Research Park and looking to the future, discussions are already underway to scope Chesterford’s next phase of speculative development; it’s an incredibly exciting time for the Park.”

Yvette Stallwood, Head of Applied Protein Services (APS), Lonza Pharma & Biotech added: “Relocating the Cambridge site operations from Granta Park to Chesterford Research Park allows us to continue to expand our operations and services to support our customers.  Increased capacity in the Gonville Building will provide laboratory and office space to further advance risk assessment and development of early-stage biotherapeutics and vaccines. The refurbishment programme is already underway and we plan to relocate the Cambridge operations in Q1 2020.”

For more information on APS Services visit: https://www.lonza.com/custom-manufacturing/development-technologies/protein-and-vaccine-development-services.aspx

Chesterford Research Park provides an innovative, flexible and future-proofed environment for both established and early-stage pharmaceutical, biotechnology and technology research and development companies, including Arecor, AstraZeneca, Cambridge Epigenetix, Charles River Laboratories, Domainex, Isogenica and Isomerase. To date, more than 350,000 sq ft of laboratory R&D space has been let and occupied. Further phases of construction are proposed to extend the development to approximately 1 million sq ft.

Chesterford Research Park’s uniquely low-density development, set within 250 acres of impressive parkland, offers not only ultra-modern and energy efficient laboratory and office space, but also central ‘hub’ facilities within the purpose-built The Nucleus building. At the heart of the Park, the Nucleus houses a restaurant, café bar, health and fitness centre, and meeting and conferencing space, all of which can be accessed and enjoyed by both occupiers and visitors on a daily basis.

To find out more about Chesterford Research Park, including current availability please visit: www.chesterfordresearchpark.com